Medication Monitor

Generic Name (Trade Name—Company)
July 1, 2019


Pfizer gains approval for its oncology biosimilar, bevacizumab-bvzr

Pfizer has received FDA approval for bevacizumab-bvzr, a biosimilar to bevacizumab (Avastin), for treatment of five types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent, or metastatic nonsquamous non–small cell lung cancer (NSCLC); recurrent glioblastoma; metastatic renal cell carcinoma (RCC); and persistent, recurrent, or metastatic cervical cancer.

It works by inhibiting the formation of new blood cells (angiogenesis) by specifically recognizing and binding to vascular endothelial growth factor (VEGF) protein. 

FDA approval was based on review of a comprehensive data package that demonstrated biosimilarity of bevacizumab-bvzr to the reference product.

The most common adverse reactions are epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, back pain, and exfoliative dermatitis.

See the prescribing information for dosage instructions.